Answers are grounded in this paper and cite their sources.
Real-world database study shows ipragliflozin/insulin lowers severe hypoglycemia risk in type 1 diabetes, indicating safe use with monitoring.
Ipragliflozin/insulin combination therapy showed no difference in the incidence of DKA, but a lower incidence of SH, versus insulin therapy in patients with T1D in Japan. These results suggest that ipragliflozin treatment is not associated with increased incidences of initial DKA or SH; however, its use should be accompanied by appropriate monitoring, education, and risk mitigation strategies to minimize the occurrence of these events.
No takes yet. Share an insight, caveat, or question.
Kawamura et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: